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Response to 5-fluorouracil in 
metastatic extramammary Paget 
disease of the scrotum presenting 
as pancytopenia and back pain
ABSTRACT
Extramammary Paget disease is a rare intraepithelial 
neoplasm of the vulvar, penoscrotal, or perianal skin. 
No effective therapies for metastatic disease have 
been reported, and prognosis for metastatic disease 
is poor.
Here, we report the case of an asian man who 
was initially diagnosed with extramammary Paget 
disease of the scrotum. Three years later, the patient 
presented to hospital with pancytopenia and back 
pain. after an extensive work-up, biopsies of liver and 
bone marrow revealed adenocarcinoma with signet 
cells and immunohistochemical staining positive for 
keratin 7, carcinoembryonic antigen, and prolactin-
induced protein, but negative for keratin 20, S100, and 
prostate markers, consistent with his previous biopsy-
proven Paget disease of the scrotum. The patient was 
treated with 5-fluorouracil–based therapy in addition 
to palliative radiotherapy to selected spine levels. a 
promising palliative response was demonstrated fol-
lowing 5-fluorouracil chemotherapy.
a review of the literature on the pathogenesis, 
diagnosis, treatment options, and outcomes for meta-
static extramammary Paget disease is presented.
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1.  CASE REPORT
a 67-year-old asian man presented to a community 
hospital after several weeks of severe fatigue and 
back pain requiring opioid analgesics. He denied 
fevers, night sweats, weight loss, gastrointestinal 
bleeding, and obstructive urinary symptoms. He had 
a prior history of a remote right middle cerebral artery 
territory stroke with residual hemiparesis, diabetes, 
hypertension, hypercholesterolemia, and 60 pack–
years of cigarette smoking. Three years earlier, he had 
been diagnosed with biopsy-proven extramammary 
Paget disease of the scrotum. He initially failed to 
respond to topical steroids, and he declined Mohs 
micrographic surgery. He was therefore treated with 
imiquimod for 1 year with complete resolution on 
re-biopsy. Since that time, colonoscopy had been 
performed with no abnormalities identified, and he 
had been well in the interim. His family history was 
negative for malignancy.
at presentation, this patient’s physical examina-
tion was remarkable only for left-sided pyramidal 
neurologic findings, hepatomegaly, and a diffusely 
enlarged prostate. Initial lab work found pancytope-
nia with leukoerythroblastic features, and repeated 
red blood cell and platelet transfusions were sub-
sequently required. Serum creatinine, calcium, and 
liver function tests were within normal limits. Com-
puted tomography (c t ) imaging showed moderate 
left hilar and para-aortic lymphadenopathy, multiple 
liver lesions, bi-lobar prostate enlargement, and left 
hydronephrosis secondary to ureteral obstruction. a 
left ureteral stent was placed.
a transrectal prostate biopsy showed Gleason 
3+4 adenocarcinoma in 3 of 8 core specimens with-
out perineural or extraprostatic extension. Prostate-
specific antigen was 17.7 ng/mL. In contrast with 
the prostate biopsy, bone marrow aspiration and 
biopsy demonstrated marrow packed with poorly 
differentiated adenocarcinoma with signet ring cells 
showing positive immunohistochemical staining for 
keratin 7 (k r t 7) and prolactin-induced protein (p i p: 
Figure 1), and also carcinoembryonic antigen (c e a), 
but without staining for prostate-specific antigen, 
prostate-specific acid phosphatase, P504S, CD45, 
keratin 20 (k r t 20), vimentin, TTF1, CDX2, S100, 
or estrogen receptors. Fine-needle aspiration biopsy 
of a liver lesion was also performed and showed 
adenocarcinoma cells with signet ring morphology, 
again unlike the prostate findings. Re-examination 
of a previous scrotal skin biopsy confirmed the 
presence of extramammary Paget disease, but also 
showed the presence of signet ring cells with k r t 7, 
c e a , and p i p immunostaining (Figure 2) identical 
to that seen in the bone marrow and liver biopsies. 
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were also present. dermal invasion by Paget cells 
was not evident, but could not be ruled out because 
of the superficial nature of the biopsy. Serum c e a 
was elevated at 24 μg/L, but alfa fetoprotein and 
cancer antigen 19-9 were normal at 1.5 μg/L and 
<2×103 U/l respectively.
On repeat c t  scan, lesser sac and celiac lymph-
adenopathy were now present, as were lytic lesions 
in the pelvis and in all vertebral bodies, with com-
pression fractures at sites of pain at T5, T8, and l1. 
a bone scan using 99Tc revealed widespread skeletal 
metastases, including vertebral involvement at mul-
tiple levels.
The patient received palliative radiotherapy in 
a single fraction of 800 cGy using a direct posterior 
field. Given the signet ring differentiation on the 
bone marrow and liver biopsies, an occult upper 
gastrointestinal malignancy was suspected, and a gas-
troduodenoscopy was performed, which was normal. 
Metastatic extramammary Paget disease remained the 
lead diagnostic possibility on the differential.
despite a poor performance status, the patient 
received a single cycle of dose-reduced bolus 
5-fluorouracil (5f u: 325 mg/m2 daily for 5 days) and 
leucovorin (20 mg/m2 daily for 5 days) with intent 
to assess treatment tolerance and response. Within 
1 week, the patient’s need for red blood cell transfu-
sions every other day ceased, and his hemoglobin 
remained stable for the next 2 months. His energy 
level and appetite improved, his weight stabilized, 
and his analgesic use markedly diminished with an 
improvement of his Eastern Cooperative Oncology 
Group performance status to 1. Following a second 
cycle of bolus 5f u and leucovorin chemotherapy, c t  
imaging showed improvement in the size and appear-
ance of the liver lesions; however, skeletal disease 
was unchanged. The level of c e a  declined to 16 μg/L 
from 24 μg/L.
The patient received a third cycle of 5f u and 
leucovorin before being switched to oral capecitabine 
1000 mg/m2 twice daily for 14 days, repeated every 
21 days. He completed three such cycles with mini-
mal side effects, but became increasingly fatigued, 
jaundiced, and confused before the fourth cycle. red 
blood cell transfusions were again needed, and c e a  
increased to 67 μg/L.
after a 20-week period of disease control on 
therapy, c t  imaging showed progression of the liver 
disease with new ascites and peritoneal carcinoma-
tosis. active treatment was discontinued, and the 
patient was transferred to a hospice, where he died 
6.2 months from the time of presentation. an autopsy 
was not performed.
2.  DISCUSSION
Extramammary Paget disease is a rare intraepithelial 
neoplasm of the vulvar, penoscrotal, or perianal skin 
typically presenting as well-circumscribed erythema-
tous pruritic plaques that can erode, weep, and form 
crusts 1. Patients are predominantly between 50 and 
80 years of age, and the disease is more frequent in 
females, except in asian populations 2. The condition 
is often misdiagnosed as seborrheic dermatitis, lichen 
sclerosis, Bowen disease, eczema, psoriasis, or a su-
perficial fungal infection, and multiple unsuccessful 
attempts at dermatologic treatment are common. It is 
thought to arise from either pluripotent keratinocyte 
stem cells or epidermal apocrine gland cells, and it 
leads to a primary adenocarcinoma in situ within the 
epidermis or adnexal structures 3. less commonly, 
an underlying adenocarcinoma can extend into the 
epidermis leading to a secondary form of the disease 3. 
Malignancies associated with extramammary Paget 
disease include cancers of the urethra, bladder, pros-
tate, colon, vagina, cervix, or endometrium 4.
Paget cells occasionally exhibit signet ring dif-
ferentiation because of the presence of intracyto-
plasmic sialomucin 1. Whereas primary cutaneous or 
ectodermic extramammary Paget disease expresses 
f i g u r e  1  Bone marrow biopsy.
f i g u r e  2  Scrotal skin biopsy.83
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the sweat gland immunohistochemical marker p i p, the 
secondary form is usually negative for this marker 
and instead expresses k r t 20 5,6. Expression of c e a  is 
common to both types. Extramammary Paget disease 
is sometimes associated with invasion of the dermis 
or with lymph node involvement, and its metastatic 
potential is believed to be limited 7,8.
diagnosis requires a high index of suspicion; the 
history and physical examination should be directed 
at identifying an underlying malignancy, particularly 
if the secondary form of the disease is suspected. 
Tumour markers, imaging studies, and invasive pro-
cedures such as endoscopy or biopsies of other sites 
should be similarly targeted. Treatment for noninva-
sive disease is wide local excision, with Mohs surgery 
achieving improved local recurrence rates 9. radiation 
therapy is an acceptable alternative in situations in 
which surgery might be functionally destructive, or 
when the disease has recurred after excision 10. No ef-
fective chemotherapy regimens for locally advanced 
or metastatic extramammary Paget disease have been 
established, and combinations of agents mentioned 
in case reports include 5f u plus mitomycin C 11, 
carboplatin plus 5f u and leucovorin 12, low-dose 5f u 
plus cisplatin 13,14, single-agent docetaxel 15, and mi-
tomycin C plus epirubicin, vincristine, cisplatin, and 
5f u  16. response rates cannot be estimated from these 
studies, but local control and the occasional complete 
response have been documented.
This case represents a rare presentation of wide-
spread metastases secondary to extramammary Paget 
disease of the scrotum, with a demonstrated meaning-
ful palliative response to 5f u-based therapy.
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